Crucially, the natural compound sulforaphane demonstrates therapeutic potential by targeting this pathway to suppress glioma cell growth, positioning ACTL6A as both a prognostic biomarker and a druggable target for glioblastoma treatment.112 Furthermore, targeting the signaling pathways associated with ACTL6A in conjunction with existing chemotherapy or targeted therapies may enhance treatment effectiveness and help overcome resistance.12 This evidence concerns the gene ACTL6A and central nervous system cancer.